Pharmaceutical composition for stimulation of angiogenesis
First Claim
1. A pharmaceutical composition for induction of blood vessel tissue growth, the composition comprising:
- purified plasmid DNA encoding a human recombinant vascular endothelial growth factor (VEGF), wherein the VEGF encoding sequences are operatively linked to expression control sequences to provide gene expression in human cells, and from 200 to 400 mM of glucose and from 3 to 30 mM of sodium phosphate, wherein the pharmaceutical composition is an isotonic solution, and wherein a concentration of the purified plasmid DNA in the composition is from 0.1 to 10 mg/ml, and a pH of the composition is form 7.0 to 9.0.
1 Assignment
0 Petitions
Accused Products
Abstract
Provided is a pharmaceutical composition for growth induction in blood vessel tissue which contains purified plasmid DNA encoding a vascular endothelial growth factor (VEGF) and pharmaceutically acceptable excipients that include a cryoprotectant as a vehicle and/or a pH stabilizer for stabilizing the pH in the range of 7.0 to 9.0, in effective quantities. Also provided is a storage method of plasmid DNA which encodes a VEGF comprising mixing the purified plasmid DNA with a solution of at least one cryoprotectant having properties of a vehicle and/or a pH stabilizer in the pH range of 7.0-9.0. The solution is lyophilized and stored at +2 to +8° C. Supercoiled DNA pCMV-VEGF165 may be used which is produced by culturing Esherichia coli strain TOP10/pCMV-VEGF165. The pharmaceutical composition is administered to a human in quantities sufficient to provide a necessary therapeutic effect. The provided pharmaceutical composition of plasmid DNA pCMV-VEGF165 does not change significantly properties of the active substance when stored for a long time at a temperature from +2 to +8° C.
6 Citations
19 Claims
-
1. A pharmaceutical composition for induction of blood vessel tissue growth, the composition comprising:
purified plasmid DNA encoding a human recombinant vascular endothelial growth factor (VEGF), wherein the VEGF encoding sequences are operatively linked to expression control sequences to provide gene expression in human cells, and from 200 to 400 mM of glucose and from 3 to 30 mM of sodium phosphate, wherein the pharmaceutical composition is an isotonic solution, and wherein a concentration of the purified plasmid DNA in the composition is from 0.1 to 10 mg/ml, and a pH of the composition is form 7.0 to 9.0. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
12. A pharmaceutical composition for induction of blood vessel tissue growth the composition comprising
from 0.8 to 1.2 mg/ml of the purified plasmid DNA comprising the polynucleotide sequence of SEQ ID NO: - 1;
from 280 to 320 mM of dextrose; and from 8 to 12 mM of sodium phosphate, wherein the pH of the composition is from 7.4 to 8.2.
- 1;
-
13. A method for storage of purified plasmid DNA which encodes a human recombinant vascular endothelial growth factor (VEGF), the method comprising:
-
adding from 200 to 400 mM of glucose and from 3 to 30 mM of sodium phosphate to the purified plasmid DNA, thereby obtaining an isotonic solution, subsequently lyophilizing the isotonic solution, thereby obtaining a lyophilizate, and storing the lyophilizate at a temperature of from +2°
C. to +8°
C.,wherein a concentration of the purified plasmid DNA in the isotonic solution prior to the lyophilizing is from 0.1 to 10 mg/ml, and a pH of the isotonic solution is from 7.0 to 9.0. - View Dependent Claims (14, 15, 16, 17)
-
-
18. A pharmaceutical composition comprising:
-
purified plasmid DNA encoding a human recombinant vascular endothelial growth factor (VEGF), wherein the VEGF encoding sequences are operatively linked to expression control sequences to provide gene expression in human cells, and wherein the purified plasmid DNA comprises the polynucleotide sequence of SEQ ID NO;
1, andfrom 3 to 30 mM of sodium phosphate and from 200 to 400 mM of glucose to make the pharmaceutical composition isotonic, and wherein a concentration of the purified plasmid DNA in the composition is from 0.1 to 10 mg/ml, and a pH of the composition is form 7.4 to 9.0. - View Dependent Claims (19)
-
Specification